Aradigm Corp fka ARDMQ

[rikic]

Strong Buy PT $26 (AnalystsReview.com)

http://get.analystsreview.com/pdf/?c=Aradigm&d=26-Feb-2015&s=ARDM

Aradigm Corporation (Aradigm) announced that the European Patent Office has granted key composition of matter for Pulmaquin in Europe and Australia. The patent is entitled "Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile" (E.U. Patent No. 2,079,443), and has been issued to Aradigm for formulations of liposomal and free ciprofloxacin. This patent provides coverage for Aradigm's lead product candidate, the inhaled ciprofloxacin drug Pulmaquin®, in Europe until at least October 23, 2027. In its release dated January 1, 2015, Aradigm revealed that the Company also has four issued U.S. patents and one issued Japanese patent (JP5254239) which provide coverage for Pulmaquin in the U.S. until 2031 and in Japan until 2027. "Long term patent protection of our lead product Pulmaquin is an important component of our corporate strategy," said Igor Gonda, Aradigm's President and CEO. "Our global efforts in this area are running in parallel with our Phase 3 clinical trials of Pulmaquin for non-cystic fibrosis bronchiectasis currently being conducted across five continents in 14 different countries."